Breaking News Instant updates and real-time market news.

NFLX

Netflix

$334.48

-1.62 (-0.48%)

, AMZN

Amazon.com

$1,527.24

23.92 (1.59%)

06:27
04/19/18
04/19
06:27
04/19/18
06:27

Netflix plans to spend $1B on European original productions in 2018, FT reports

Netflix (NFLX) is planning to more than double its 2017 production budget for Europe in 2018 with the intention to spend roughly $1B on original productions for the region this year, the Financial Times reports, citing people briefed on the investment plans. The increase, which is expected to almost double the number of European productions in 2018, will create challenges for traditional broadcasters who are already struggling with ways to attract in retain viewers amid elevated competition from Netflix and other streaming players like Amazon (AMZN). Reference Link

NFLX

Netflix

$334.48

-1.62 (-0.48%)

AMZN

Amazon.com

$1,527.24

23.92 (1.59%)

  • 26

    Apr

NFLX Netflix
$334.48

-1.62 (-0.48%)

04/17/18
PIVT
04/17/18
NO CHANGE
Target $420
PIVT
Buy
Netflix price target raised to $420 from $400 at Pivotal Research
Pivotal Research analyst Jeffrey Wlodarczak noted that Netflix reported better than expected Q1 subscriber additions and raised its operating margin expectations. Following the report, he raised his subscriber forecasts for 2018 and 2019 and lowered his 2018 cost view moderately, leading Wlodarczak to increase his price target on the stock to $420. He maintains a Buy rating on Netflix shares.
04/17/18
BMOC
04/17/18
NO CHANGE
Target $324
BMOC
Market Perform
Netflix price target raised to $324 from $310 at BMO Capital
BMO Capital analyst Daniel Salmon raised his price target on Netflix to $324 after the company's above-consensus Q1 earnings and Q2 guidance. Salmon says the company has made improvements on churn, developed more original content, and accomplished more with its distribution partnerships while also demonstrating its marketing effectiveness and boosting its per-subscriber leverage. The analyst is keeping his Market Perform rating on Netflix as shares "properly value" the company's opportunity, but adds that a "pullback/controversy/new story" would lead him to consider a more bullish stance.
04/17/18
RBCM
04/17/18
NO CHANGE
Target $360
RBCM
Outperform
Netflix price target raised to $360 from $350 at RBC Capital
RBC Capital analyst Mark Mahaney raised his price target on Netflix to $360 after the company's "very strong" Q1 results, saying 2018 looks to be an "inflection year" for the stock. The analyst cites Q1 net subscriber adds' consensus beat of 32% for domestic and 9% for international segments, while the outlook for Q2 was above the Street by 23% and 19% respectively. Mahaney also points to improving profitability, as Netflix domestic contribution margin expanded by 400bps to 38% and international margin reached a record high of 15%. The analyst keeps his Outperform rating on Netflix, maintaining his view of the company's "King of Content" position amid a rapid global ramp in demand for internet TV.
04/18/18
ARGS
04/18/18
NO CHANGE
ARGS
Hold
Netflix valuation remains 'significantly higher' than peers, says Argus
Argus analyst Joseph Bonner kept his Hold rating on Netflix (NFLX) but raised his FY18 EPS view to $2.89 from $2.73 after the company's Q1 earnings beat. The analyst says the company is benefiting from the "secular growth of internet-delivered on-demand video" but also warns that it is taking on more debt, resulting in a "stunning" cash-burn rate. Bonner adds that the market is still judging the company by its subscriber growth while overlooking the costs associated with the ramp in content production and content licensing. The analyst is also cautious on Netflix valuation as its trailing enterprise value to EBITDA multiple is 136-times relative to 29-times peer average and 48-times at Amazon (AMZN).
AMZN Amazon.com
$1,527.24

23.92 (1.59%)

04/17/18
WELS
04/17/18
NO CHANGE
WELS
Amazon reluctance to enter pharmacy positive for food service, says Wells Fargo
Wells Fargo analyst Edward Kelly notes that CNBC reported that Amazon has decided not to pursue a bulk pharmacy offering within its Amazon Business segment. The analyst believes that this decision, if true, could represent a positive read-through for the food distribution business. It has been reported that the key reasons Amazon may not pursue pharmacy include its complex distribution network requiring cold-chain storage, firmly entrenched customer relationships, high costs associated with entry, and difficulty in supplying the appropriate breadth of product, he points out, noting that these hurdles are similar to the barriers to entry in food service.
04/18/18
MSCO
04/18/18
UPGRADE
Target $58
MSCO
Overweight
eBay upgraded to Overweight from Underweight at Morgan Stanley
Morgan Stanley analyst Brian Nowak upgraded eBay (EBAY) two notches, to Overweight from Underweight, as expects the company to start pulling away from PayPal (PYPL) and intermediating its own payments in 2018, with a planned full transition in mid-2020. He is bullish about this initiative, noting that other leading platforms - including Amazon (AMZN), Booking (BKNG), and others - have seen higher user conversion and spending from more integrated and comprehensive payment offerings, Nowak tells investors. Not only can payments drive faster GMV growth, it can also add 20% to companywide EBIT, Nowak estimates. He raised his price target on eBay shares to $58 from $36.
04/19/18
PIPR
04/19/18
NO CHANGE
Target $1650
PIPR
Overweight
Amazon online retail segment could miss Q1 estimates, says Piper Jaffray
Piper Jaffray analyst Michael Olson says his firm's Amazon Search Index indicates Q1 online unit growth will be 21% year-over-year versus 23% in Q4, suggesting revenue that is slightly below Street expectations for the online retail segment. However, given the "strong cloud backdrop" and Piper's chief investment officer survey indicating an intent to accelerate spend, Amazon Web Services could partially offset any softness in retail, Olson tells investors in a pre-earnings research note. He also sees a high likelihood of "other" segment revenue upside in Q1 from advertising. Investors should own Amazon shares for the "plethora of topline tailwinds" and the potential for a return to margin expansion in the second half of 2018, Olson contends. He reiterates an Overweight rating on the shares with a $1,650 price target.

TODAY'S FREE FLY STORIES

03:15
11/15/18
11/15
03:15
11/15/18
03:15
General news
FX Action: USD-CAD has settled in the lower 1.3200s »

FX Action: USD-CAD has…

02:30
11/15/18
11/15
02:30
11/15/18
02:30
General news
FX Update: The Dollar has traded broadly softer »

FX Update: The Dollar has…

01:50
11/15/18
11/15
01:50
11/15/18
01:50
General news
Asian Market Wrap: »

Asian Market Wrap:…

APTX

Aptinyx

$24.75

-0.76 (-2.98%)

21:40
11/14/18
11/14
21:40
11/14/18
21:40
Initiation
Aptinyx initiated at Cantor Fitzgerald »

Aptinyx initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OVID

Ovid Therapeutics

$4.75

-0.42 (-8.12%)

21:39
11/14/18
11/14
21:39
11/14/18
21:39
Initiation
Ovid Therapeutics initiated at Cantor Fitzgerald »

Ovid Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

AXSM

Axsome Therapeutics

$2.82

-0.07 (-2.42%)

21:38
11/14/18
11/14
21:38
11/14/18
21:38
Initiation
Axsome Therapeutics initiated at Cantor Fitzgerald »

Axsome Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DNLI

Denali Therapeutics

$17.53

0.24 (1.39%)

21:37
11/14/18
11/14
21:37
11/14/18
21:37
Initiation
Denali Therapeutics initiated at Cantor Fitzgerald »

Denali Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTIC

Otonomy

$2.34

-0.07 (-2.90%)

21:35
11/14/18
11/14
21:35
11/14/18
21:35
Initiation
Otonomy initiated at Cantor Fitzgerald »

Otonomy initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

AAPL

Apple

$186.81

-5.42 (-2.82%)

20:46
11/14/18
11/14
20:46
11/14/18
20:46
Hot Stocks
Apple supplier AMS AG discontinues FY18 targets »

Ams updates its fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

WEI

Weidai

$0.00

(0.00%)

20:33
11/14/18
11/14
20:33
11/14/18
20:33
Syndicate
Weidai 4.5M share IPO priced at $10.00 »

The deal was priced at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

CPB

Campbell Soup

$39.16

-0.1 (-0.25%)

20:31
11/14/18
11/14
20:31
11/14/18
20:31
Hot Stocks
Campbell Soup responds to ISS regarding board elections »

Campbell Soup issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

CRM

Salesforce

$129.25

-2.93 (-2.22%)

20:25
11/14/18
11/14
20:25
11/14/18
20:25
Periodicals
Breaking Periodicals news story on Salesforce »

Salesforce to accommodate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

  • 06

    Dec

  • 11

    Dec

  • 03

    Mar

WMT

Walmart

$101.58

-1.37 (-1.33%)

, JCP

J.C. Penney

$1.23

-0.05 (-3.91%)

20:25
11/14/18
11/14
20:25
11/14/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

WMT

Walmart

$101.58

-1.37 (-1.33%)

JCP

J.C. Penney

$1.23

-0.05 (-3.91%)

BERY

Berry Global

$45.91

-0.49 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

BHVN

Biohaven Pharmaceutical

$33.70

-3.18 (-8.62%)

19:53
11/14/18
11/14
19:53
11/14/18
19:53
Recommendations
Biohaven Pharmaceutical analyst commentary at Piper Jaffray »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 27

    Nov

LOXO

Loxo Oncology

$143.69

-15.62 (-9.80%)

19:51
11/14/18
11/14
19:51
11/14/18
19:51
Initiation
Loxo Oncology initiated at Raymond James »

Loxo Oncology initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

  • 26

    Nov

  • 27

    Nov

OCUL

Ocular Therapeutix

$5.06

-0.25 (-4.71%)

19:50
11/14/18
11/14
19:50
11/14/18
19:50
Initiation
Ocular Therapeutix initiated at Raymond James »

Ocular Therapeutix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Dec

VYGR

Voyager Therapeutics

$11.25

-0.54 (-4.58%)

19:49
11/14/18
11/14
19:49
11/14/18
19:49
Upgrade
Voyager Therapeutics rating change at Raymond James »

Voyager Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

GLPG

Galapagos NV

$103.79

1.03 (1.00%)

19:48
11/14/18
11/14
19:48
11/14/18
19:48
Initiation
Galapagos NV initiated at Raymond James »

Galapagos NV initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COPY

CopyTele

$0.00

(0.00%)

19:47
11/14/18
11/14
19:47
11/14/18
19:47
Upgrade
CopyTele rating change at BMO Capital »

CopyTele upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICI

VICI Properties

$21.43

-0.04 (-0.19%)

19:40
11/14/18
11/14
19:40
11/14/18
19:40
Syndicate
VICI Properties 30M share Secondary priced at $21.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

WHD

Cactus

$32.37

-0.7 (-2.12%)

19:37
11/14/18
11/14
19:37
11/14/18
19:37
Hot Stocks
Cactus names Stephen Tadlock new CFO »

Cactus announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RVLT

Revolution Lighting

$1.42

(0.00%)

19:32
11/14/18
11/14
19:32
11/14/18
19:32
Hot Stocks
Revolution Lighting receives revised $1.50 per share proposal from RVL LLC »

Revolution Lighting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$8.34

-0.265 (-3.08%)

19:20
11/14/18
11/14
19:20
11/14/18
19:20
Periodicals
General Electric withdraws from Nigeria rail concession, Reuters says »

GE has withdrawn from a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCSF

Bain Capital Specialty Finance

$0.00

(0.00%)

19:11
11/14/18
11/14
19:11
11/14/18
19:11
Syndicate
Bain Capital Specialty Finance 7.5M share IPO price $20.25 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

TSLA

Tesla

$344.07

5.36 (1.58%)

19:07
11/14/18
11/14
19:07
11/14/18
19:07
Periodicals
Tesla Model 3 owners experience issues in cold weather, Electrek says »

Tesla Model 3 will face…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 19

    Nov

  • 19

    Nov

  • 13

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.